top of page
Browse by category
Search
Improving GLP-1 drug delivery by fusing the peptide directly to immunoglobulin antibodies
Massachusetts Institute of Technology (MIT) researchers have revealed a drug delivery system that "paints" glucagon-like peptide-1...
OAC and TOS urge FDA to enforce GLP-1s compounding regulations
The Obesity Action Coalition (OAC) and The Obesity Society (TOS) have sent a letter to the FDA, along with more than 20 leading...
Combination of the Allurion Program with low-dose GLP-1 therapy to optimise muscle mass and GLP-1 adherence
Allurion Technologies has announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimise...
Why women experience stronger side effects from GLP-1s
There are fundamental sex-based differences in how weight loss medications interact with human biology, according to a study by Olio...
SOS: Partial weight recurrence after substantial weight loss increases vascular disease
Partial weight recurrence after substantial weight loss was associated with a less favourable cardiovascular risk profile and an...
Biolexis reveals allosteric activation mechanism for the GLP-1 receptor
Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the...
Browse by tag
bottom of page